A COMPARISON OF PERPHENAZINE, PROKETAZINE, NIALAMIDE AND MO-482 IN CHRONIC SCHIZOPHRENICS
NAUTTAM J. KOTHARI M.D.1,
JOHN C. SAUNDERS M.D.1,
NATHAN S. KLINE M.D.1, , and
JOSEPH A. GRIFFEN M.D.2
1 Research Facility, Rockland State Hospital, Orangeburg, N. Y. and College of Physicians and Surgeons, Columbia University, New York City.
2 Rockland State Hospital, Orangeburg, N. Y.
Of 25 chronic schizophrenics in each group on perphenazine and proketazine, 11 patients on each drug showed improvement. The patients with delusions, hallucinations and hyperactivity had the maximal benefit from these psychoinhibiting drugs. Of 25 chronic schizophrenics in each group, 11 improved with nialamide and 7 with MO-482. Seven patients on perphenazine and 8 on proketazine improved either to a moderate or marked degree. Moderate to marked improvement was seen in 3 and 5 patients on nialamide and MO-482 respectively. Apathetic and autistic patients had the maximal benefit from the psychoactivating drugs. These drugs are relatively safe as no serious untoward clinical or laboratory results were observed.
